Cutaneous T-cell lymphoma (mycosis fungoides)

Lancet

Volumn 347, Issue 9005, 1996, Pages 871-876

  Lorincz, Allan L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPRURITIC AGENT; CARMUSTINE; CHLORMETHINE; PSORALEN;

ARTICLE; CANCER STAGING; ELECTRON BEAM; HUMAN; MYCOSIS FUNGOIDES; ORAL DRUG ADMINISTRATION; PIGMENTATION; PRIORITY JOURNAL; PUVA; RACE DIFFERENCE; SEX DIFFERENCE; SEZARY SYNDROME; SKIN LYMPHOMA; T CELL LYMPHOMA; TOPICAL DRUG ADMINISTRATION; ULTRAVIOLET B RADIATION;

EID: 0029987064     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)91350-1     Document Type: Article

References (30)

1. Sézary A, Bouvrain Y. Erythrodermie avec présence de cellules monstreuses dans derme et sang circulant. Bull Soc Fr Dermatol Syph 1938; 45: 254-60.
2. Rappaport H, Thomas LB. Mycosis fungoides: the pathology of extracutaneous involvement. Cancer 1974; 34: 1198-229.
3. Long JC, Mihm MC. Mycosis fungoides with extracutaneous dissemination: a distinct clinicopathologic entity. Cancer 1974; 34: 1745-55.
4. Braverman IM. Cutaneous T-cell lymphoma. Curr Probl Dermatol 1991; 3: 181-233.
5. Kuzel TM, Roenigk HH Jr, Rosen ST. Mycosis fungoides and the Sézary syndrome: a review of pathogenesis, diagnosis and therapy. J Clin Oncol 1991; 9: 1298-313.
6. Abel EA, Wood GS, Hopps RT. Mycosis fungoides: clinical and histologic features, staging, evaluation, and approach to treatment. CA Cancer J 1993; 43: 93-115.
7. Weinstock MA, Horm JW. Mycosis fungoides in the United States: increasing incidence and descriptive epidemiology. JAMA 1988; 260: 42-46.
8. Whittemore AS, Holly EA, Lee IM, et al. Mycosis fungoides in relation to environmental exposures and immune respone: a case-control study. J Natl Cancer Inst 1989; 81: 1560-67.
9. Greene MH, Pinto HA, Kant JA, et al. Lymphomas and leukemias in the relatives of patients with mycosis fungoides. Cancer 1982; 49: 737-41.
10. Zucker-Franklin D, Coutavas EE, Rush MG, Zouzias C. Detection of human T-lymphotropic virus-like particles in cultures of peripheral blood lymphocytes from patients with mycosis fungoides. Proc Natl Acad Sci 1991; 88: 7630-34.
11. Hall WW, Liu CR, Schneewind O, et al. Deleted HTLV-1 provirus in blood and cutaneous lesions of patients with mycosis fungoides. Science 1991; 253: 317-20.
12. Manzari V, Gismoni A, Barillari G, et al. A new human retrovirus isolated in a tac-negative T-cell lymphoma/leukemia. Science 1987; 238: 1581-83.
13. Keil H. Parapsoriasis en plaques disséminées and incipient mycosis fungoides. Arch Dermatol Syph 1937; 37: 465-94.
14. Wieselthier JS, Koh HK. Sézary syndrome: diagnosis, prognosis, and critical review of treatment options. J Am Acad Dermatol 1990; 22: 381-401.
15. Lutzner MA, Jordan HW. The ultrastructure of an abnormal cell in Sézary syndrome. Blood 1968; 31: 719-26.
16. Edelson R, Facktor M, Andrews A, et al. Successful management of the Sézary syndrome: mobilization and removal of extravascular neoplastic T cells by leukapheresis. N Engl J Med 1974; 291: 293-94.
17. McNutt MS, Crain WR. Quantitative electron microscope comparison of lymphocyte nuclear contours in mycosis fungoides and in benign infiltrates in the skin. Cancer 1981; 47: 698-709.
18. Breathnach SM, McKee PH, Smith NP. Hypopigmented mycosis fungoides: report of five cases with ultra-structural observations. Br J Dermatol 1982; 106: 340-45.
19. Barnhill RL, Braverman IM. Progession of pigmented purpura-like eruptions to mycosis fungoides: report of three cases. J Am Acad Dermatol 1988; 19: 25-31.
20. Proceedings of the workshop on cutaneous T-cell lymphomas (mycosis fungoides and Sézary syndrome). Cancer Treat Rep 1979; 63: 561-736.
21. Sausville EA, Worsham GF, Matthews MJ, et al. Histologic assessment of lymph nodes in mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system. Hum Pathol 1985; 16: 1098-109.
22. Sausville EA, Eddy JL, Makuch RW, et al. Histopathologic staging at initial diagnosis of mycosis fungoides and Sézary syndrome: definition of three distinctive prognostic groups. Ann Intern Med 1988; 109: 372-82.
23. O'Loughlin S, Diaz-Perez JL, Gleich GJ, et al. Serum IgE in dermatitis and dermatosis: an analysis of 497 cases. Arch Dermatol 1977; 113: 309-15.
24. Kupper TS, Edelson RL. The role of cytokines in the pathophysiology of T cell mediated skin disease. J Dermatol 1987; 14: 517-23.
25. Vonderheid EC, Tan E, Kantor AF, et al. Long-term efficacy, curative potential and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T-cell lymphoma. J Am Acad Dermatol 1989; 20: 416-28.
26. Ratner AC, Waldorf DS, Van Scott EJ. Alterations of lesions of mycosis fungoides lylmphoma by direct imposition of delayed hypersensitivity reactions. Cancer 1968; 21: 83-88.
27. Zackheim HS, Epstein EH Jr, Crain WR. Topical carmustine (BCNU) for cutaneous T-cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol 1990; 22: 802-10.
28. Roenigk HH Jr, Kuzel TM, Skoutelis AP, et al. Photochemotherapy alone or combined with interferon alfa-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 1990; 95 (suppl): 198S-205S.
29. Edelson RL, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987; 316: 297-303.
30. Hoppe RT, Cox TS, Fuks Z, et al. Electron-beam therapy for mycosis fungoides: the Stanford experience. Cancer Treat Rep 1979; 63: 691-700.